Merrimack Pharmaceuticals Inc. Announces the Addition of Former Deloitte Global CEO James H. Quigley to Its Board of Directors
CAMBRIDGE, Mass., July 16, 2012 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced the election of James Quigley, CEO emeritus of Deloitte Touche Tohmatsu, Limited (the Deloitte Global Network), to its Board of Directors. Merrimack is a biopharmaceutical company dedicated to the discovery and development of novel medicines for the treatment of cancer.